CGIM
CRSP icon

Capital Group Investment Management’s CRISPR Therapeutics CRSP Stock Holding History

Capital Group Investment Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$639K Hold
11,707
– – 0.1% 129
2026
Q1 		$557K Hold
11,707
– – 0.1% 129
2025
Q4 		$614K Sell
11,707
-1,236
-10% -$74K 0.1% 129
2025
Q3 		$839K Buy
12,943
+798
+7% +$45.8K 0.14% 120
2025
Q2 		$591K Sell
12,145
-2,427
-17% -$93.9K 0.11% 129
2025
Q1 		$496K Sell
14,572
-13,126
-47% -$556K 0.1% 127
2024
Q4 		$1.09M Buy
27,698
+582
+2% +$27.5K 0.21% 100
2024
Q3 		$1.27M Hold
27,116
– – 0.26% 93
2024
Q2 		$1.46M Buy
27,116
+535
+2% +$30.9K 0.32% 78
2024
Q1 		$1.81M Buy
26,581
+6,485
+32% +$464K 0.32% 88
2023
Q4 		$1.26M Sell
20,096
-958
-5% -$53K 0.13% 136
2023
Q3 		$956K Buy
21,054
+533
+3% +$27.5K 0.06% 145
2023
Q2 		$1.15M Hold
20,521
– – 0.06% 143
2023
Q1 		$928K Buy
20,521
+646
+3% +$31.4K 0.05% 154
2022
Q4 		$808K Buy
+19,875
New +$1.05M 0.03% 164

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Capital Group Investment Management's CRSP Position: Q2 2026 in Review

Capital Group Investment Management held its CRISPR Therapeutics (CRSP) position steady in Q2 2026 at 11,707 shares worth $639K. The position accounts for 0.1% of the portfolio, ranked #129.

Capital Group Investment Management first reported a position in CRSP in Q4 2022 and has held it in 15 quarters since. The position peaked at $1.81M in Q1 2024. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Capital Group Investment Management held 11,707 shares of CRISPR Therapeutics worth $639K as of Q2 2026.
  • Capital Group Investment Management left its CRISPR Therapeutics share count unchanged in Q2 2026.
  • CRISPR Therapeutics made up 0.1% of Capital Group Investment Management's portfolio in Q2 2026, its #129 holding.
  • Capital Group Investment Management first reported a position in CRISPR Therapeutics in Q4 2022 and has held it in 15 quarters since.
  • Capital Group Investment Management's CRISPR Therapeutics position peaked at $1.81M in Q1 2024.
  • 521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Capital Group Investment Management's 13F filing for Q2 2026, filed 12 Aug 2026.